- Home
- DXLG vs COEP Comparison
DXLG vs COEP Comparison
Compare DXLG & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | COEP |
|---|---|---|
| Founded | 1976 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 100.4M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXLG | COEP |
|---|---|---|
| Price | $1.19 | $15.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 223.2K | 91.6K |
| Earning Date | 12-11-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $442,120,000.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $2.31 |
| 52 Week High | $3.10 | $21.41 |
Technical Indicators
Market Signals| Indicator | DXLG | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 45.46 |
| Support Level | $1.01 | $14.82 |
| Resistance Level | $1.58 | $16.45 |
| Average True Range (ATR) | 0.15 | 1.47 |
| MACD | 0.04 | -0.21 |
| Stochastic Oscillator | 35.77 | 4.78 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.